Fibrogen Inc SEC Filings

KYNTRA BIO, INC. Chief Financial Officer David DeLucia reported a small tax-related share disposition. On the vesting of restricted stock units, 60 shares of common stock were withheld by the company to cover his tax obligations. After this withholding, he directly owns 4,429 common shares.

This was a tax-withholding disposition, not an open-market sale or purchase, so it mainly reflects routine equity compensation mechanics rather than a change in his investment view on the company.

FibroGen Inc. Schedule 13G/A: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 400,000 shares of common stock, representing 9.89% of the class as of 12/31/2025. The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder, and that the Master Fund has the right to receive dividends or sale proceeds. Steven Boyd is identified as managing member of Armistice Capital and files jointly with the firm.

Kyntra Bio, Inc. reported that CEO and director Thane Wettig received a grant of stock options. On February 3, 2026, he was awarded options to purchase 60,000 shares of common stock at an exercise price of $8.50 per share, with no cash price paid for the grant itself.

The options vest in equal amounts quarterly over four years starting from February 3, 2026, and are exercisable until February 2, 2036. Following this award, Wettig beneficially owns 60,000 stock options, held directly.

Kyntra Bio, Inc. reported an option grant to its Chief Financial Officer, David DeLucia. On 02/03/2026, he was awarded a stock option for 26,000 shares of common stock at an exercise price of $8.50 per share.

The option vests in equal amounts quarterly over four years starting on 02/03/2026. Following this grant, DeLucia beneficially owns 26,000 derivative securities directly through this option award.

FibroGen, Inc. has changed its corporate name to Kyntra Bio, Inc. following the filing of a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the State of Delaware on December 29, 2025. The name change becomes effective at 4:30 p.m. Eastern Time on January 7, 2026.

The board also approved a conforming amendment to the company’s Bylaws, effective at the same time, to update the Bylaws’ title to Kyntra Bio, Inc. In connection with the rebranding, the company’s common stock, previously trading under the symbol “FGEN” on The Nasdaq Global Select Market, will begin trading under the new symbol “KYNB” at the market open on January 8, 2026. The CUSIP number for the common stock remains unchanged.

FibroGen, Inc. (FGEN) reported insider buying by its Chief Executive Officer and Director in a Form 4 filing. On 11/13/2025, the reporting person purchased 1,000 shares of common stock at $9.18 per share. On 11/17/2025, an additional 2,700 shares were purchased at $9.0999 per share. After these transactions, the reporting person beneficially owned 24,939 shares of FibroGen common stock directly and 40 shares indirectly through a spouse. The filing was made by a single reporting person in the roles of both CEO and Director.

FibroGen, Inc. (FGEN) reported Q3 2025 results highlighted by the divestiture of its China operations to AstraZeneca for total consideration of $220.4 million. The company received $210.4 million at closing on August 29, 2025 and used approximately $80.9 million to repay its senior secured term loan facilities, interest, and related fees.

Results reflect discontinued operations for China: income from discontinued operations was $213.8 million in the quarter, including a $52.2 million gain on divestiture. From continuing operations, revenue was $1.1 million and loss was $13.1 million. Net income was $200.6 million, driven by the discontinued operations gain. Cash and cash equivalents were $118.0 million as of September 30, 2025, up from $50.5 million at year-end 2024.

The company effected a 1‑for‑25 reverse stock split on June 16, 2025. Shares outstanding were 4,045,445 as of October 31, 2025. Management now believes existing cash will fund planned operating requirements for at least 12 months following issuance. FibroGen initiated a Phase 2 study of FG‑3246 in mCRPC and aligned with the FDA on key elements of a planned Phase 3 for roxadustat in lower‑risk MDS.

FibroGen, Inc. furnished an 8-K to announce it issued a press release with financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1.

The company states the information under Item 2.02, including Exhibit 99.1, is not deemed “filed” under the Exchange Act and will not be incorporated by reference into other SEC filings.

FibroGen, Inc. reported receipt of a $6.4 million payment from AstraZeneca. The amount reflects release of the first $6.0 million holdback under their February 20, 2025 share purchase agreement, plus $0.4 million from final net cash adjustments after closing.

This relates to FibroGen’s August 29, 2025 sale of its China operations to AstraZeneca for approximately $220 million, comprised of $85 million in enterprise value and about $135 million in net cash held in China. Of the total, $210 million was paid at closing, with an additional $10.0 million subject to holdbacks: the now-released $6.0 million cash-adjustment holdback and a separate $4.0 million indemnity holdback to be released, net of any claims paid or unresolved, nine months after closing.